This study is looking at whether a blood test called Signatera Genome can help guide treatment for women with early-stage endometrial cancer (cancer of the lining of the uterus) that is considered high-intermediate risk. The study wants to see if women who are found to be "ctDNA negative" (meaning no circulating tumor DNA is detected in their blood after surgery) can safely choose observation instead of vaginal brachytherapy (a type of internal radiation therapy). Researchers will compare the recurrence-free survival (how long patients live without their cancer coming back) at 3 years for women who are observed versus those who receive vaginal brachytherapy. You may be able to join if you are a woman aged 18 or older with early-stage, high-intermediate risk endometrial cancer. The current recruitment status is unclear.

Study design

This is a randomized study with 1010 planned participants. It compares two groups of patients to see if one treatment approach is as good as another.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your recurrence-free survival will be measured for 3 years from the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.